Esperion Therapeutics (ESPR) Misses Q1 EPS by 12c

Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.79), $0.12 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $24.3 million versus the consensus estimate of $21.86 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• RBC Capital Reiterates Sector Perform Rating on ExxonMobil (XOM)
• Westinghouse said to seek over $50 billion valuation in planned IPO